72nd Heidelberg Grand Round - Integrative Radiation Oncology

Europe/Berlin
Description

 

 

 

 

 

This year, the NCT Heidelberg is again organizing several Heidelberg Grand Rounds. The format is aimed at clinicians as well as  researchers and provides a platform for effective scientific exchange. Recognized experts will present the latest clinical and research results in selected oncological fields.

We look forward to welcoming you to the virtual conference room.  

Please note that the time indicated corresponds to Central European Time (CET).

Chairs: 

Prof. Dr. Dr. Jürgen Debus 
National Center for Tumor Diseases (NCT) Heidelberg /
Heidelberg University Hospital (UKHD

Prof. Dr. Dr. Amir Abdollahi
German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ) /
Heidelberg University Hospital (UKHD)

 

Participation is free of charge. Registration online is possible until 28 November. 

 

Thanks to our sponsor: 

MSD Sharp & Dohme GmbH - 800 €

 



The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and German Cancer Aid (DKH).

Organizer: Heidelberg University Hospital (UKHD)
Event language: English

Note:  If the registration form does not open, please change your browser (e.g. to Google Chrome, Firefox or Microsoft Edge) and try again.

Registration
Registration
    • 16:00 16:30
      Development of methylome based biomarker for personalized radiotherapy 30m
      Speaker: Dr Bouchra Tawk (German Cancer Consortium (DKTK) Heidelberg University Hospital (UKHD))
    • 16:30 17:00
      Novel developments @ Biophysics in particle therapy - BioPT 30m
      Speaker: Dr Andrea Mairani (National Center for Tumor Diseases (NCT) Heidelberg / Heidelberg Ion-Beam Therapy Center (HIT)
    • 17:00 17:30
      Novel developments at the interface of tumor immunology and radiotherapy – RadImmune 30m
      Speaker: Prof. Eric Deutsch (Gustave Roussy )
    • 17:30 18:00
      Personalized peptide vaccination 30m
      Speaker: Prof. Hans-Georg Rammensee (University of Tübingen / German Cancer Consortium (DKTK))